Gerresheimer show strong second quarter growth
Gerresheimer AG has shown strong growth in the second quarter of 2021. Revenues increased organically by 7.5%, with revenues in the core business growing by 7.1% year on year, generating €377 million.
“The new company focus on sustainable growth, innovation and providing solutions for our customers is bearing fruits. We revealed our strengths in the second quarter. Prefillable syringes and other high-value solutions such as for biotech drugs are the main drivers. The delivery of injection vials is running as planned. We expect a strong second half of the year and confirm our guidance for 2021,” says Dietmar Siemssen, CEO.
In the second quarter of 2021, the Plastics & Devices Division recorded organic growth of 4.4%.
The company achieved considerable growth in revenues in pharmaceutical primary packaging solutions made of plastic and in the syringes business in particular. Organic revenues in the Primary Packaging Glass Division rose by 10.3% year on year.
Significant revenue increases were recorded for high-value solutions in particular, such as Elite Glass products.
Adjusted EBITDA in the core business stood at €85 million, corresponding to an organic growth of 3.1%. The organic adjusted EBITDA margin in the core business amounted to 22.8%.
Adjusted net income stood at €41 million. Adjusted earnings per share stood at €1.28, which is a year-on-year increase of 19.1%.
Outlook for the financial year 2021 (core business, currency adjusted): revenue growth in the mid-single-digit percentage range; adjusted EBITDA margin between 22% and 23%; and adjusted earnings per share to improve by around 10%.
